Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...
Hosted on MSN19h
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Merck director Douglas Baker acquires $1.33 million in stock
Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...